Our research findings suggest that Trametinib, through selective inhibition of MEK1/2, can significantly suppress pancreatic cancer cell proliferation and effectively halt the cell cycle progression, thus inducing cell death. This evidence concerns the gene MAP2K1 and pancreatic neoplasm.